Skip to content
The Nexus
DossierENTITY

Cancer drugs

Coverage of Cancer drugs in the Nexus archive.

Earliest in view: Apr 10 · 03:42 UTCMost recent: Jul 28 · 19:01 UTC
Co-mentioned in this coverage
Kalshiorganization1Polymarketorganization1FDAorganization1The New York Timesorganization1Clinical Trialstopic1prediction marketstopic1insider tradingtopic1Lokayuktaorganization1Karnataka governmentorganization1BET inhibitorstopic1BRD2topic1BRD4topic1Gene activationtopic1
Recent coverage
  • HEALTHJul 28 · 19:01 UTCBATON ROUGE BUSINESS REPORT
    Prediction market wagering on drug approvals draws fire from researchers

    Betting platforms Kalshi and Polymarket are allowing users to wager on FDA drug approvals and clinical trial outcomes, sparking criticism from researchers, doctors, and patients over risks to scientific integrity and public trust. Critics argue prediction markets could influence trial behavior and enable insider trading, while Kalshi claims they offer valuable insights and have safeguards against insider participation.

  • HEALTHJul 6 · 15:10 UTCTHE HINDU NATIONAL
    Lokayukta directs Karnataka govt. to act on cancer drug availability

    The Lokayukta has directed the Karnataka government to take action regarding the availability of cancer drugs.

  • HEALTHApr 10 · 03:42 UTCSCIENCE DAILY
    Scientists finally uncover why promising cancer drugs keep failing

    Scientists have identified why BET inhibitors, a class of cancer drugs, have failed in clinical trials. The research shows BRD2 and BRD4 proteins have distinct roles in gene activation, with BRD2 acting as a 'stage manager' and BRD4 triggering gene activation. Blocking both proteins simultaneously disrupts the process, leading to inconsistent drug effectiveness.